The Crosstalk between Fat Homeostasis and Liver Regional Immunity in NAFLD

Minjuan Ma,1 Rui Duan,1 Hong Zhong,1 Tingming Liang,1 and Li Guo2

1Jiangsu Key Laboratory for Molecular and Medical Biotechnology and College of Life Sciences, Nanjing Normal University, Nanjing, Jiangsu 210023, China
2Department of Bioinformatics, School of Geographic and Biologic Information, Nanjing University of Posts and Telecommunications, Nanjing, Jiangsu 210023, China

Correspondence should be addressed to Tingming Liang; tmliang@njnu.edu.cn and Li Guo; lguo@njupt.edu.cn

Received 24 June 2018; Revised 11 November 2018; Accepted 9 December 2018; Published 3 January 2019

Guest Editor: Xiaoni Kong

Copyright © 2019 Minjuan Ma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The liver is well known as the center of glucose and lipid metabolism in the human body. It also functions as an immune organ. Previous studies have suggested that liver nonparenchymal cells are crucial in the progression of NAFLD. In recent years, NAFLD’s threat to human health has been becoming a global issue. And by far, there is no effective treatment for NAFLD. Liver nonparenchymal cells are stimulated by lipid antigens, adipokines, or other factors, and secreted immune factors can alter the expression of key proteins such as SREBP-1c, ChREBP, and PPARγ to regulate lipid metabolism, thus affecting the pathological process of NAFLD. Interestingly, some ncRNAs (including miRNAs and lncRNAs) participate in the pathological process of NAFLD by changing body fat homeostasis. And even some ncRNAs could regulate the activity of HSCs, thereby affecting the progression of inflammation and fibrosis in the course of NAFLD. In conclusion, immunotherapy could be an effective way to treat NAFLD.

1. Introduction

The liver, consisting of 80% hepatic parenchymal cells and 20% hepatic nonparenchymal cells, is the largest metabolism organ in the human body. It not only maintains the homeostasis of sugars and fats but also participates in immune regulation (innate immunity, adaptive immunity, and immune tolerance) [1–3]. Hepatocytes are hepatic parenchymal cells, while the other 20% of nonparenchymal cells in the liver include liver sinusoidal endothelial cells (LSECs), natural killer (NK) cells, natural killer T (NKT) cells, Kupffer cells (KCs), hepatic stellate cells (HSCs), and dendritic cells (DCs). Hepatocytes, the parenchymal cells of the liver, are stimulated by a number of inflammatory factors, such as interleukin 6 (IL-6) and interleukin 1 beta (IL-1β), producing a large number of acute-phase proteins (APPs) that can kill foreign antigens and regulate immune responses [4]. KCs play an important role in the initial response to injury. When liver damage occurs, it can rapidly produce cytokines and chemokines, such as IL-1β and tumor necrosis factor α (TNF-α), resulting in the recruitment of other immune cells, such as monocytes. After entering the liver, the phenotype of monocytes changes, showing proinflammatory and profibrotic functions [5]. NK cells play an important role in liver host defense and immune balance by secreting cytokines, such as interferon gamma (IFN-γ) [6]. NKT cells serve as a bridge connecting innate immunity and adaptive immunity in the liver. They are activated by stimulation with lipid antigens, rapidly secrete anti-inflammatory or proinflammatory cytokines and chemokines, and participate in liver diseases [7]. A recent study shows that LSECs are serving as sentinel cells to detect microbial infection through pattern recognition receptor activation and as antigen-presenting cells [8]. Under normal physiological conditions, HSCs store liver lipids and 70% of the body’s vitamin A. Conversely, after being stimulated by insulin, they can secrete type I collagen (Col-1) and connective tissue growth factor, causing inflammation and liver fibrosis [9]. Liver DCs internalize antigens and present them to surrounding lymphocytes as APCs and regulate T cells via the interleukin 10
Liver disease (viral hepatitis, liver fibrosis, fatty liver, alcoholic liver, drug-induced liver damage and cirrhosis, and liver cancer), relating to liver immune cell disorders, is one of the reasons for high mortality in some countries and regions of the world [12-14]. Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease, the primary feature of which is simple steatosis caused by accumulation of liver triglycerides (TG), followed by nonalcoholic steatohepatitis (NASH) with inflammation, fibrosis, and liver damage, eventually developing into cirrhosis and hepatocellular carcinoma (HCC). Importantly, it is also closely related to obesity and type 2 diabetes, insulin resistance (IR), and other metabolic abnormalities [15, 16]. It has been reported that the prevalence of NAFLD is about 27%-34% in America [17], 25% in Europe [18], and 15-20% in Asia [19]. With economic development and changes in lifestyle, the upward trend of people’s weights, especially in some high-income countries and regions, is causing global obesity and type 2 diabetes [20, 21]. Population-based studies showed that 2.6–9.6% of children have NAFLD, increasing up to 38–53% among obese children [22, 23]. Therefore, prevention and treatment of NAFLD is an imminent global issue.

NAFLD begins with excessive accumulation of TG in the liver. Studies have shown that approximately 60% of TG comes from adipose tissue free fatty acid pools, 26% from dietary fatty acids, 15% from unhealthy diets [24]. Obesity and type 2 diabetes promote liver overload of glucose and insulin, which can activate carbohydrate response element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c), respectively, thereby upregulating glycolytic enzymes and fatty acid synthase to promote hepatic lipogenesis [25]. Interestingly, IL-1β signaling mediates hepatic TG accumulation by driving the de novo lipogenic signaling pathway in obese mouse livers [26]. The main reason for the development of NASA from simple steatosis is abnormal release of adipokines and excessive accumulation of liver TG to activate hepatic nonparenchymal cells such as KCs, DCs, NK, and NKT. These cells can release proinflammatory factors including TNF-α, IL-6, and TGF-β, thereby leading to hepatitis, liver fibrosis, and liver damage [27].

Complex crosstalk between hepatocytes and other hepatocytes plays a decisive role in the pathogenesis of NAFLD. Surprisingly, some noncoding RNAs (ncRNAs) are involved in the pathological process of NAFLD and can even directly regulate certain pathways in liver nonparenchymal cells to influence the progression of NAFLD (Table 1). Therefore, this paper mainly clarifies the interaction between immune factors and ncRNA and protein in each stage of NAFLD, in order to provide potential targets for the treatment and prognosis of NAFLD.

### 2. Crosstalk between Hepatocytes, Hepatic Nonparenchymal Cells, and Adipocytes in the Pathological Process of NAFLD

#### 2.1. Main Signal Pathways in Simple Hepatic Steatosis

Liver fat is mainly derived from dietary fatty acids, de novo lipogenesis, and adipose tissue. Hepatic steatosis occurs when fatty acid uptake, de novo lipogenesis, lipid secretion, or disposal via free fatty acid (FFA) oxidation are unbalanced [28].

Dietary fat is stored in fat tissue in the form of FFA to form an FFA pool. Obesity causes dysfunction of adipocytes and releases a large number of proinflammatory factors such as TNF-α [29], IL-6 [30], and leptin. This causes FFAs in the FFA pool to translocate to nonadipose tissues such as the liver and skeletal muscle [31]. At the same time, TNF-α inhibits the release of adiponectin by adipocytes, thereby increasing the uptake of hepatic FFAs and reducing hepatic fatty acid oxidation and TG output [32]. Excessive accumulation of FFAs causes IR [33], which can mobilize peripheral fat to form new FFAs. FFAs translocate to the liver, exacerbate liver TG accumulation, and ultimately cause hepatic steatosis [34].

De novo fatty acid synthesis is a complex reaction, and it is regulated by multiple factors [35]. This paper mainly describes the FFAs from de novo fatty acid synthesis through the pathways involved in the three proteins SREBP-1c, ChREBP, and PPARγ. SREBP-1c is an isoform of SREBPs (a family of TFs anchored in the ER membrane). It mainly regulates the synthesis of fatty acids [36]. ChREBP is a

| Noncoding RNAs                      | Target genes | Signaling pathways                  | References |
|-------------------------------------|--------------|-------------------------------------|------------|
| MiR-373                             | AKT1         | AKT–mTOR–S6K                        | [91]       |
| MiR-7a                              | YY1          | YY1-CHOP10-C/EBP-α/PPARγ            | [92]       |
| MiR-130a-3p                         | TGFBR1/TGFBR2| GF-β/SMAD                           | [93]       |
| MiR-26a                             | IL-6 mRNA    | miR-26a-IL-6-IL-17 axis             | [94]       |
| MiR-146a-5p                         | Wnt1 and Wnt5a| Wnt                                  | [95]       |
| LncRNA MRAK052686                   | Nrf2 and Eif2ak2| PERK                                | [99]       |
| LncRNA SRA                          | FoxO1        | FFA β-oxidation                     | [100]      |
| LncRNA MALAT1                       | CXCL5        | Extracellular space                 | [101]      |
| LncRNA NONRATT013819.2              | Lox          | ECM-related pathways                | [102]      |
transcription factor that recognizes the carbohydrate response element (ChRE) in glycosylation and lipid synthesis gene promoter [37, 38]. The peroxisome proliferator-activated receptors (PPARs), transcription factors that regulate lipid metabolism and insulin sensitivity [39], consist of three isoforms: PPARγ, PPARα, and PPARδ [40]. PPARγ is highly expressed in adipocytes while it is also present in other hepatocytes, especially in resting HSCs [41].

IR can upregulate SREBP-1c, ChREBP, and PPARγ to promote hepatic steatosis, which in turn can promote IR by SREBP-1c, ChREBP, and PPARγ. (1) The proinflammatory factors TNF-α and IL-6 released by M1-type KCs (regulated by lipopolysaccharide and other factors) reach the hepatic portal vein with blood flow and form a functional complex with hepatocyte membrane receptors TNFR1 and IL-6R [42–44]. The complex formed by TNF-α and TNFR1 recruits upstream kinases such as nuclear factor-κB (NF-κB) inducible kinase (NIK) and transforming growth factor-β-activated kinase to activate NF-κB, which upregulates IL-6 expression and cytokine signaling inhibitor-3 (SOCS-3) by binding to DNA [45]. IL-6 activates the Janus-activated kinase (JAK), which in turn is activated by phosphorylation of signal transduction and activator of transcription 3 (STAT3), which upregulates SOCS-3 [46]. SOCS-3 promotes IR by inducing the expression of SREBP-1c, which suppresses insulin receptor-mediated IRS1/2 synthesis [47]. (2) When IR causes severe extrahepatic injury, the liver tissue receives overloaded glucose and insulin. Insulin activates SREBP-1c [48]. SREBP-1c activates transcription of transcription factors involved in FFA metabolism, including the cluster of differentiation 36 (CD36) required for FFA uptake [49], FFA synthesis of required fatty acid synthase (FASN) and acetyl-CoA carboxylase (ACC), and TG synthesis-required glycerol-3-phosphate acyltransferase [50, 51]. High concentration of glucose induces the transfer of ChREBP from the cytoplasm to the nucleus; ChREBP in the nucleus upregulates FASN and ACC [52] and also induces glucose-6 phosphatase (G6P) and liver pyruvate kinase (LPK) expression to accelerate glycolysis and gluconeogenesis [53]. Interestingly, a recent study [54] found that activated ChREBP can directly target SREBP-1c and promote the accumulation of FFAs. (3) The large amount of FFAs released by adipose tissue activates liver PPARγ, which upregulates fatty acid transporters (such as CD36), resulting in a significant increase in fatty acid uptake in hepatocytes. The fatty acid is then converted to fatty acyl CoA, which is ultimately esterified to TG. In addition, hepatic PPARγ upregulates monoacylglycerol O-acyltransferase 1 (MGAT1) expression to promote TG accumulation [55]. PPARγ also upregulates SREBP-1c expression to promote de novo synthesis of lipids [56].

2.2. Main Signal Pathways in NASH. The main pathological features of NASH are (1) oxidative stress (OS) [57], (2) systemic and hepatic inflammation [58], (3) fibrosis [59], and (4) hepatocyte apoptosis [60]. The appearance of these pathological features is mainly triggered by the accumulation of excessive FFAs in the liver to activate the signaling pathways that promote prooxidation, proinflammation, profibrosis, and proapoptosis [61].

FFAs are stored in lipid droplets in the form of TG, exported as very low-density lipoprotein (VLDL), and oxidized by mitochondrial β-oxidation. Excessive activation of mitochondrial β-oxidation and cytochrome P450 family 2 subfamily E member 1 (CYP2E1), a cytochrome that performs futile cycles with release of electrons into the cytosol, which destroy the electron transport chain, produces a large amount of reactive oxygen species (ROS), which ultimately leads to OS [62, 63]. TNF-α can effectively stimulate the production of mitochondrial ROS [64]. In order to reduce ROS, a large amount of mitochondrial uncoupling protein is produced to reduce superoxide anions, which unfortunately leads to a decrease in membrane potential, thereby limiting ATP production. When the ATP supply is insufficient, dying KCs release the proinflammatory factor interleukin 8 (IL-8). This recruits inflammatory cells into the liver [65].

FFAs activate proinflammatory signals through TLR4 and in a synergistic manner with LPS [66, 67]. Proinflammatory cells (including hepatocytes, KCs, and adipocytes) produce proinflammatory factors through NF-κB activation [68]. LPS targets and activates TLR4 in hepatocytes and KCs, which upregulates NF-κB transcription to produce a large number of proinflammatory factors including IL-β, TNF-α, IL-6, IL-8, and TGF-β [69]. KCs can also be activated by OS to promote the release of proinflammatory factors (IL-β, TNF-α, IL-6, IL-8, and TGF-β) [70]. The dysfunctional adipocytes release a large amount of the proinflammatory factors TNF-α and IL-6 [30]. The massive release of proinflammatory factors promotes the conversion of simple hepatic steatosis to NASH. At the same time, proinflammatory factors in turn promote IR, thus aggravating NAFLD. Adipocytes can release two adipokines, leptin and adiponectin, which are involved in inflammation and fibrosis to affect the pathological process of NASH [71]. Adiponectin reduces inflammation by stimulating KCs to secrete anti-inflammatory cytokines (such as IL-10), blocking the activation of NF-κB [72], and inhibiting the release of TNF-α, IL-6, and chemokines, and antifibrosis by activating AMP-activated protein kinase (AMPK) in HSCs [73, 74]. Leptin accelerates the development of NASH by upregulating the expression of CD14 in KCs (enhancing the response of hepatocytes to low-dose LPS) [75]. It can also promote fibrosis by targeting KCs and sinusoidal endothelial cells, releasing a large amount of TGF-β, which promotes HSC production of collagen [76–79]. Unfortunately, low expression of adiponectin and high expression of leptin promote the development of inflammation and fibrosis in the NAFLD.

NF-κB upregulates the expression of TNF-α, Fas ligand (FasL), and TGF-β, which are considered to be major factors in the response to apoptosis and fibrosis that drive NASH progression [80]. After TNF-α and FasL recognize and bind to receptor TNFR and Fas on hepatocytes, respectively, TNFR and Fas are activated, which triggers a series of apoptotic events. Homologous dimerization of activated TNFR and Fas induces the formation of the death-inducing signaling complex (DISC), which induces activation of caspases 8 and 10, and induction of caspase 3, 6, and 7, eventually
leading to hepatocyte apoptosis [81, 82]. Upon activation of NKT cells by lipid antigens, CD40L expression is upregulated on the surface of NKT cells, which interacts with CD40 expressed on DCs, resulting in the production of IL-12 by DCs [83]. Increased liver IL-12 levels further stimulate liver NKT cells to enhance cytotoxicity by releasing perforin and granzymes and increasing the expression of FasL on the surface, which expresses binding to Fas receptors expressed on hepatocytes, leading to apoptosis [84]. Activation of NKT cells can also indirectly induce hepatocyte apoptosis by the release of cytokines, including IFN-γ and TNF-α. NKT-derived IFN-γ activates and recruits NK cells and DCs. Specifically, NK cell-induced transactivation of NK cells enhances cytolyis and production of NK cell IFN-γ, thereby further promoting hepatocyte apoptosis [85, 86].

The phosphorylation of SMAD2/3 is triggered by the interaction of TGF-β produced by KCs with specific receptors on the membrane of HSCs. Phosphorylated SMAD2/3 forms a complex with SMAD4 and is transferred to the nucleus to upregulate Col-1 in combination with target genes, thereby promoting fibrosis [87, 88].

3. ncRNAs Link the Fat Homeostasis and Immunity in the Progression of NAFLD

Noncoding RNA (ncRNA) refers to an RNA that does not encode any protein. ncRNA includes RNAs of known functions such as rRNA, tRNA, snRNA, snoRNA, and microRNA, as well as RNAs of unknown function. ncRNA plays an important role in the process of life. For example, ncRNAs can regulate mRNA stability and translation and ncRNAs affect protein stability and transport [89]. In the chapter, we will focus on the role of microRNA and lncRNA in the progression of NAFLD.

microRNAs (miRNAs) are endogenous, noncoding RNAs of about 20-24 nucleotides in length that can interact with messenger RNA and participate in posttranscriptional regulation of gene expression [90]. Studies have shown that the upregulation of microRNA-373 (miR-373) lowers its target gene AKT serine/threonine kinase 1 (AKT1) mRNA levels, resulting in suppression of the AKT-mTOR-S6K signaling pathway in hepatocytes and eventually weakening hepatic lipid abnormal deposition [91]. In zebrafish, the depletion of miR-7a increases the expression of Yin Yang 1 (YY1). YY1 induces the expression of C/EBP-α and PPARγ by inhibiting the expression of CHOP-10, leading to the accumulation of FFAs and triglyceride, and finally causing NASH [92]. MiR-130a-3p promotes the apoptosis of HSCs and inhibits the production of collagen by inhibiting the TGF-β/SMAD signaling pathway, thereby improving the pathological process of the liver [93]. Overexpression of miR-26a improves NAFLD and reduces IL-17 expression by partially reducing IL-6 expression, indicating the immunomodulatory effects of the miR-26a-IL-6-IL-17 axis in the pathological process of NAFLD. However, the specific mechanism of immune regulation has not been elucidated [94]. MiR-146a-5p inhibits the activity and proliferation of HSCs by downregulating Wnt1 and Wnt5a; the amount of Col-1 is decreased, thereby inhibiting the occurrence of fibrosis in the progression of NAFLD [95]. Several of the above studies indicate that miRNAs affect a particular signaling pathway by targeting their specific target genes, thereby regulating lipid-metabolizing proteins, as well as hepatic nonparenchymal cells involved in NAFLD progression. So, miRNAs may serve as new targets for NAFLD.

Long-chain noncoding RNAs are noncoding RNAs with a length of more than 200 nt, which have important functions in transcriptional silencing, transcriptional activation, chromosomal modification, and nuclear transport [96, 97]. As transcription factors, lncRNAs play an important role in normal physiological and pathological processes [98]. In 2015, a study reported that Berberine (BBR) can upregulate the expression of IncRNA MRAK052686 and its target genes Nrf2 and Eif2ak2 in a high-fat diet- (HFD-) induced steatotic animal model, thereby inhibiting the PERK (PKR-like ER-kinease) pathway in ER stress, indicating that IncRNA MRAK052686 plays a role in NAFLD by affecting ER stress. This study opened the prelude to the study of the role of IncRNAs in NAFLD [99]. IncRNA SRA inhibits the transcription of forkhead box protein O1 (FoxO1) through an insulin-independent pathway in hepatocytes, thereby reducing the expression of the downstream gene adipsiglyceride lipase (ATGL) and subsequently lowering the FFA β-oxidation of hepatocytes, resulting in hepatic steatosis [100]. Some IncRNAs are involved in immune regulation by regulating nonparenchymal liver cells. Studies have found that in activated HSCs, IncRNA MALAT1 expression is upregulated and upregulates its target C-X-C motif chemokine ligand 5 (CXCL5), thereby promoting the development of inflammation and fibrosis in NASH [101]. Correspondingly, the study found that IncRNA NONRATT013819.2 was involved in ECM-related pathways to mediate activation of HSCs by upregulating the expression of lysyl oxidase (Lox) [102]. lncRNAs are not only involved in the development of NAFLD, but also related to the occurrence of HCC [103]. Most importantly, lncRNAs are involved in immune regulation [104], indicating that lncRNAs can be used as a novel target for liver immunotherapy.

4. Conclusions and Immune Treatment Strategies in NAFLD

Nowadays, the number of people suffering from NAFLD is increasing rapidly [105]. However, because of the complicated pathogenic mechanism behind NAFLD, there is currently no effective treatment for NAFLD. During the NAFLD process, hepatocytes, hepatic nonparenchymal cells, and adipocytes crosstalk, releasing factors involved in hepatic steatosis, nonalcoholic steatohepatitis, fibrosis, and even HCC [106]. Accumulation of fatty acids causes liver steatosis, endoplasmic reticulum resistance, and reactive oxygen species to promote steatosis and development into NASH [108]. By far, the existing methods for treating NAFLD include improving diet, strengthening exercise, changing lifestyles, and performing weight loss surgery, all with the purpose of reducing the accumulation of liver fat in patients [109–114]. Studies on NAFLD have reported that there is a
complicated relationship between liver immunity and fat homeostasis [115–117], while there is evidence that ncRNAs can interact with nonparenchymal liver cells and affect NAFLD [118]. Many functions of ncRNAs are not to be noted. Liver nonparenchymal cells play a crucial role in the maintenance of liver morphological structure and function (Figure 1). Although there are no reports of immunotherapy of NAFLD associated with fatty acid metabolism, future researches on the relationship between ncRNAs and NAFLD, between liver nonparenchymal cells and NAFLD, or the effect of interaction between ncRNAs and liver nonparenchymal cells on NAFLD, and liver immunotherapy for NAFLD
could be a breakthrough point in addressing current treatment deficiencies. Therefore, searching the target of NAFLD immunotherapy could be a new direction in the research for the treatment of NAFLD.

**Abbreviations**

| Abbreviation | Description |
|--------------|-------------|
| NK           | Natural killer cells |
| NKT          | Natural killer T cells |
| LSECs        | Liver sinusoidal endothelial cells |
| IL-6         | Interleukin 6 |
| IL-1β        | Interleukin 1 beta |
| APPs         | Acute-phase proteins |
| KCs          | Kupffer cells |
| TNF-α        | Tumor necrosis factor α |
| IFN-γ        | Interferon gamma |
| HSCs         | Hepatic stellate cells |
| NAFLD        | Nonalcoholic fatty liver disease |
| Col-1        | Type 1 collagen |
| NASH         | Nonalcoholic steatohepatitis |
| IR           | Insulin resistance |
| SphK1        | Sphingosine kinase 1 |
| FFAs         | Free fatty acids |
| SREBP-1c     | Sterol regulatory element binding protein-1c |
| ChREBP       | Carbohydrate response element binding protein |
| PPARγ        | Peroxisome proliferator-activated receptor-γ |
| SOCS-3       | Cytokine signaling-3 |
| G6p          | Glucose-6-phosphatase |
| LPK          | L-type pyruvate kinase |
| OS           | Oxidative stress |
| VLDL         | Low-density lipoprotein |
| CYP2E1       | Cytochrome P450 family 2 subfamily E member 1 |
| FasL         | Fas ligand |
| DISC         | Death-inducing signaling complex |
| FASN         | Fatty acid synthase |
| ACC          | Acetyl-CoA carboxylase |
| IL-10        | Interleukin 10 |
| HCC          | Hepatocellular carcinoma |
| ROS          | Reactive oxygen species production |
| JNK          | c-Jun N-terminal kinase |
| MGAT1        | Monoaacylglycerol O-acyltransferase 1 |
| LPS          | Lipopolysaccharide |
| AMPK         | AMP-activated protein kinase |
| nRNA         | Noncoding RNA |
| AKT1         | AKT serine/threonine kinase 1 |
| YY1          | Yin Yang 1 |

**Conflicts of Interest**

The authors declare no conflict of interest.

**Acknowledgments**

This work was supported by the National Natural Science Foundation of China (Nos. 31401009 and 61771251), the Key Project of Social Development in Jiangsu Province (No BE2016773), the Natural Science Foundation of Jiangsu (No. BK20171443), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), and the Qing-lan Project of Nanjing Normal University sponsored by NUPTSF (Nos. NY215068, and sponsored by NUPTSF (Nos. NY215068 and NY217100).

**References**

[1] B. Gao, “Basic liver immunology,” *Cellular & Molecular Immunology*, vol. 13, no. 3, pp. 265-266, 2016.
[2] Z. Kmiec, “Cooperation of liver cells in health and disease,” *Advances in Anatomy, Embryology, and Cell Biology*, vol. 161, article 11729749, pp. 1–151, 2001.
[3] M. W. Robinson, C. Harmon, and C. O’Farrelly, “Liver immunology and its role in inflammation and homeostasis,” *Cellular & Molecular Immunology*, vol. 13, no. 3, pp. 267–276, 2016.
[4] Z. Zhou, M. J. Xu, and B. Gao, “Hepatocytes: a key cell type for innate immunity,” *Cellular & Molecular Immunology*, vol. 13, no. 3, pp. 301–315, 2016.
[5] C. Ju and F. Tacke, “Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies,” *Cellular & Molecular Immunology*, vol. 13, no. 3, pp. 316–327, 2016.
[6] H. Peng, E. Wisse, and Z. Tian, “Liver natural killer cells: subsets and roles in liver immunity,” *Cellular & Molecular Immunology*, vol. 13, no. 3, pp. 328–336, 2016.
[7] K. Bandyopadhyay, I. Marrero, and V. Kumar, “NKT cell subsets as key participants in liver physiology and pathology,” *Cellular & Molecular Immunology*, vol. 13, no. 3, pp. 337–346, 2016.
[8] S. Z. Sanz, J. B. Pucilowska, S. Liu et al., “Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injury,” *Gut*, vol. 54, no. 1, pp. 134–141, 2005.
[9] Z. M. Bamboat, J. A. Stableford, G. Pitas et al., “Human liver dendritic cells promote T cell hyporesponsiveness,” *Journal of Immunology*, vol. 182, no. 4, pp. 1901–1911, 2009.
[10] P. A. Knolle and D. Wohlleber, “Immunological functions of liver sinusoidal endothelial cells,” *Cellular & Molecular Immunology*, vol. 13, no. 3, pp. 347–353, 2016.
[11] S. L. Nozawa, J. B. Pucilowska, S. Liu et al., “Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injury,” *Gut*, vol. 54, no. 1, pp. 134–141, 2005.
[12] Z. M. Bamboat, J. A. Stableford, G. Pitas et al., “Human liver dendritic cells promote T cell hyporesponsiveness,” *Journal of Immunology*, vol. 182, no. 4, pp. 1901–1911, 2009.
[13] K. Palucka and J. Banchereau, “Cancer immunotherapy via dendritic cells,” *Nature Reviews Cancer*, vol. 12, no. 4, pp. 265–277, 2012.
[14] J. Herkel, “Regulatory T cells in hepatic immune tolerance and autoimmune liver diseases,” *Digestive Diseases*, vol. 33, no. 2, pp. 70–74, 2015.
[15] Z. Li, M. J. Soloski, and A. M. Diehl, “Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease,” *Hepatology*, vol. 42, no. 4, pp. 880–885, 2005.
[16] W. R. Kim, Brown RS Jr, N. A. Terrault, and H. el-Serag, “Burden of liver disease in the United States: summary of a workshop,” *Hepatology*, vol. 36, no. 1, pp. 227–242, 2002.
[17] B. A. Neuschwander-Tetri, “Non-alcoholic fatty liver disease,” *BMJ Medicine*, vol. 15, no. 1, pp. 45, 2017.
[18] J. T. Haas, S. Francque, and B. Staels, “Pathophysiology and mechanisms of nonalcoholic fatty liver disease,” *Annual Review of Physiology*, vol. 78, no. 1, pp. 181–205, 2016.
[19] M. Lazo, R. Hernaez, M. S. Eberhardt et al., “Prevalence of nonalcoholic fatty liver disease in the United States: the third National Health and Nutrition Examination Survey, 1988–
[8] M. Blachier, H. Leleu, M. Peck-Radosavljevic, D. C. Valla, and F. Roudot-Thoraval, "The burden of liver disease in Europe: a review of available epidemiological data," *Journal of Hepatology*, vol. 58, no. 3, pp. 593–608, 2013.

[9] G. C. Farrell, V. W. S. Wong, and S. Chitturi, "NAFLD in Asia—as common and important as in the West," *Nature Reviews Gastroenterology & Hepatology*, vol. 10, no. 5, pp. 307–318, 2013.

[10] S. Vandevijvere, C. C. Chow, K. D. Hall, E. Umali, and B. A. Swinburn, "Increased food energy supply as a major driver of the obesity epidemic: a global analysis," *Bulletin of the World Health Organization*, vol. 93, no. 7, pp. 446–456, 2015.

[11] T. Bhurosy and R. Jeeven, "Overweight and obesity epidemic in developing countries: a problem with diet, physical activity, or socioeconomic status?" *The Scientific World Journal*, vol. 2014, Article ID 964236, 7 pages, 2014.

[12] N. N. Than and P. N. Newsome, "A concise review of non-alcoholic fatty liver disease," *Atherosclerosis*, vol. 239, no. 1, pp. 192–202, 2015.

[13] Y. Falcet-Ytet, Z. M. Younossi, G. Marchesini, and A. J. McCullough, "Clinical features and natural history of non-alcoholic steatosis syndromes," *Seminars in Liver Disease*, vol. 21, no. 1, pp. 017–026, 2001.

[14] K. L. Donnelly, C. I. Smith, S. J. Schwarzenberg, J. Jessurun, M. D. Boldt, and E. J. Parks, "Sources of fatty acids stored in liver and secreted via lipoproteins in patients with non-alcoholic fatty liver disease," *Journal of Clinical Investigation*, vol. 115, no. 5, pp. 1343–1351, 2005.

[15] R. Dentin, J. Girard, and C. Postic, "Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): two key regulators of glucose metabolism and lipid synthesis in liver," *Biochimie*, vol. 87, no. 1, pp. 81–86, 2005.

[16] K. A. Negrin, R. J. Roth Flach, M. T. DiStefano et al., "IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis," *PLoS One*, vol. 9, no. 9, article e107265, 2014.

[17] I. C. Boscan, M. V. Milaciu, R. M. Pop et al., "Cytokines Genotype-Phenotype Correlation in Nonalcoholic Steatohepatitis," *Oxidative Medicine and Cellular Longevity*, vol. 2017, Article ID 4297206, 7 pages, 2017.

[18] J. M. Lou-Bonafonte, C. Arnal, and J. Osada, "New genes involved in hepatic steatosis," *Current Opinion in Lipidology*, vol. 22, no. 3, pp. 159–164, 2011.

[19] I. Nieto-Vazquez, S. Fernandez-Veledo, D. K. Kramer, R. Vila-Bedmar, L. Garcia-Guerra, and M. Lorenzo, "Insulin resistance associated to obesity: the link TNF-alpha," *Archives of Physiology and Biochemistry*, vol. 114, no. 3, pp. 183–194, 2008.

[20] T. Wang and C. He, "Pro-inflammatory cytokines: the link between obesity and osteoarthritis," *Cytokine & Growth Factor Reviews*, vol. 44, pp. 38–50, 2018.

[21] F. Bessone, M. V. Razori, and M. G. Roma, "Molecular pathways of nonalcoholic fatty liver disease development and progression," in *Cellular and Molecular Life Sciences*, pp. 1–30, Springer, 2018.

[22] H. Y. Zhang, Z. X. du, and X. Meng, "Resveratrol prevents TNFα-induced suppression of adiponectin expression via PPARγ activation in 3T3-L1 adipocytes," *Clinical and Experimental Medicine*, vol. 13, no. 3, pp. 193–199, 2013.

[23] B. Sears and M. Perry, "The role of fatty acids in insulin resistance," *Lipids in Health and Disease*, vol. 14, p. 121, 2015.

[24] S. H. Koo, "Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis," *Clinical and Molecular Hepatology*, vol. 19, no. 3, pp. 210–215, 2013.

[25] Y. Kawano and D. E. Cohen, "Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease," *Journal of Gastroenterology*, vol. 48, no. 4, pp. 434–441, 2013.

[26] J. Ou, H. Tu, B. Shan et al., "Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 11, pp. 6027–6032, 2001.

[27] H. Yamashita, M. Takenoshita, M. Sakurai et al., "A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 16, pp. 9116–9121, 2001.

[28] C. Rufo, M. Teran-Garcia, M. T. Nakamura, S. H. Koo, H. C. Towle, and S. D. Clarke, "Involvement of a unique carbohydrate-responsive factor in the glucose regulation of rat liver fatty-acid synthase gene transcription," *The Journal of Biological Chemistry*, vol. 276, no. 24, pp. 21969–21975, 2001.

[29] C. Janani and B. D. Ranjitha Kumar, "PPAR gamma gene-an overview," *Diabetes & Metabolic Syndrome*, vol. 9, no. 1, pp. 46–50, 2015.

[30] E. Esposito, S. Cuzzocrea, and R. Meli, "Peroxisome proliferator-activated receptors and shock state," *The Scientific World Journal*, vol. 6, 1782 pages, 2006.

[31] Q. Zhou, W. Guan, H. Qiao et al., "GATA binding protein 2 mediates leptin inhibition of PPARγ expression in hepatic stellate cells and contributes to hepatic stellate cell activation," *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*, vol. 1842, no. 12, pp. 2367–2377, 2014.

[32] O. H. Al-Jiffri and F. M. Alsharif, "Adipokines profile and glucose control of Saudi patients with nonalcoholic fatty liver disease," *Advanced Research in Gastroenterology & Hepatology*, vol. 5, no. 2, article 555660, 2017.

[33] C. N. Lumeng, J. L. Bodzin, and A. R. Saltiel, "Obesity induces a phenotypic switch in adipose tissue macrophage polarization," *The Journal of Clinical Investigation*, vol. 117, no. 1, pp. 175–184, 2007.

[34] Y. S. Park, M. J. Uddin, L. Piao, I. Hwang, J. H. Lee, and H. Ha, "Novel role of endogenous catalase in macrophage polarization in adipose tissue," *Mediators of Inflammation*, vol. 2016, Article ID 8675905, 14 pages, 2016.

[35] M. S. Hayden and S. Ghosh, "Regulation of NF-kB by TNF family cytokines," *Seminars in Immunology*, vol. 26, no. 3, pp. 253–266, 2014.

[36] G. Huang, M. Yuan, J. Zhang et al., "IL-6 mediates differentiation disorder during spermatogenesis in obesity-associated inflammation by affecting the expression of Zifp637 through the SOCS3/STAT3 pathway," *Scientific Reports*, vol. 6, no. 1, p. 28012, 2016.

[37] K. Ueki, T. Kadowaki, and C. Kahn, "Role of suppressors of cytokine signaling SOCS-1 and SOCS-3 in hepatic steatosis and the metabolic syndrome," *Hepatology Research*, vol. 33, no. 2, pp. 185–192, 2005.
[48] Z. G. Hua, L. J. Xiong, C. Yan et al., “Glucose and insulin stimulate lipogenesis in porcine adipocytes: dissimilar and identical regulation pathway for key transcription factors,” Molecules and Cells, vol. 39, no. 11, pp. 797–806, 2016.

[49] J. F. C. Glatz and J. J. F. P. Luiken, “From fat to FAT (CD36/SR-B2): understanding the regulation of cellular fatty acid uptake,” Biochimie, vol. 136, pp. 21–26, 2017.

[50] X. Xu, J. S. So, J. G. Park, and A. H. Lee, “Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP,” Seminars in Liver Disease, vol. 33, no. 4, pp. 301–311, 2013.

[51] N. Harada, E. Fujimoto, M. Okuyama, H. Sakaue, and Y. Nakaya, “Identification and functional characterization of human glycerol-3-phosphate acyltransferase 1 gene promoters,” Biochemical and Biophysical Research Communications, vol. 423, no. 1, pp. 128–133, 2012.

[52] S. Ishii, K. Iizuka, B. C. Miller, and K. Uyeda, “Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 44, pp. 15597–15602, 2004.

[53] R. Dentin, L. Tomas-Cobos, F. Foufelle et al., “Glucose 6-phosphate, rather than xylulose 5-phosphate, is required for the activation of ChREBP in response to glucose in the liver,” Journal of Hepatology, vol. 56, no. 1, pp. 199–209, 2012.

[54] A. G. Linden, S. Li, H. Y. Choi et al., “Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice,” Journal of Lipid Research, vol. 59, no. 3, pp. 475–487, 2018.

[55] J. H. Yu, Y. J. Lee, H. J. Kim et al., “Monoacl-glycerol O-acetyltransferase 1 is regulated by peroxisome proliferator-activated receptor γ in human hepatocytes and increases lipid accumulation,” Biochemical and Biophysical Research Communications, vol. 460, no. 3, pp. 715–720, 2015.

[56] V. Souza-Mello, “Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease,” World Journal of Hepatology, vol. 7, no. 8, pp. 1012–1019, 2015.

[57] S. Spahis, E. Delvin, J.-M. Borys, and E. Levy, “Oxidative stress as a critical factor in nonalcoholic fatty liver disease pathogenesis,” Antioxidants & Redox Signaling, vol. 26, no. 10, pp. 519–541, 2017.

[58] W. Liu, R. D. Baker, T. Bhatia, L. Zhu, and S. S. Baker, “Pathogenesis of nonalcoholic steatohepatitis,” Cellular and Molecular Life Sciences, vol. 73, no. 10, pp. 1969–1987, 2016.

[59] P. S. Dulai, S. Singh, J. Patel et al., “Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis,” Hepatology, vol. 65, no. 5, pp. 1557–1565, 2017.

[60] T. Kanda, S. Matsuoka, M. Yamazaki et al., “Aptoptosis and non-alcoholic fatty liver diseases,” World Journal of Gastroenterology, vol. 24, no. 25, pp. 2661–2672, 2018.

[61] E. Buzzetti, M. Pinzani, and E. A. Tschochatzis, “The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD),” Metabolism - Clinical and Experimental, vol. 65, no. 8, pp. 1038–1048, 2016.

[62] A. P. Rolo, J. S. Teodoro, and C. M. Palmeira, “Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis,” Free Radical Biology and Medicine, vol. 52, no. 1, pp. 59–69, 2012.

[63] M. A. Abdelmegeed, A. Banerjee, S. H. Yoo, S. Jang, F. J. Gonzalez, and B. J. Song, “Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis,” Journal of Hepatology, vol. 57, no. 4, pp. 860–866, 2012.

[64] R. A. Muluye, Y. Bian, L. Wang et al., “Placenta peptide can protect mitochondrial dysfunction through inhibiting ROS and TNF-α generation, by maintaining mitochondrial dynamic network and by increasing IL-6 level during chronic fatigue,” Frontiers in Pharmacology, vol. 7, p. 328, 2016.

[65] A. M. Diehl, “Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease,” Clinics in Liver Disease, vol. 8, no. 3, pp. 619–638, 2004.

[66] J. M. Lowe, D. Menendez, P. R. Bushel et al., “p53 and NF-κB coregulate proinflammatory gene responses in human macrophages,” Cancer Research, vol. 74, no. 8, pp. 2182–2192, 2014.

[67] H. Shi, M. V. Kokoeva, K. Inouye, I. Tzameli, H. Yin, and J. S. Flier, “TLR4 links innate immunity and fatty acid-induced insulin resistance,” The Journal of Clinical Investigation, vol. 116, no. 11, pp. 3015–3025, 2006.

[68] J. D. Schilling, H. M. Machkovech, L. He et al., “Palmitate and lipopolysaccharide trigger synergistic ceramide production in primary macrophages,” The Journal of Biological Chemistry, vol. 288, no. 5, pp. 2923–2932, 2013.

[69] X. Liu, J. Li, X. Peng et al., “Geranin inhibits LPS-induced THP-1 macrophages switching to M1 phenotype via SOCS1/NF-κB pathway,” Inflammation, vol. 39, no. 4, pp. 1421–1433, 2016.

[70] G. H. Koek, P. R. Liedorp, and A. Bast, “The role of oxidative stress in non-alcoholic steatohepatitis,” Clinica Chimica Acta, vol. 412, no. 15–16, pp. 1297–1305, 2011.

[71] S. I. Fujii and K. Shimizu, “Exploiting antitumor immunotherapeutic novel strategies by deciphering the cross talk between invariant NKT cells and dendritic cells,” Frontiers in Immunology, vol. 8, p. 886, 2017.

[72] H. Tilg and A. R. Moschen, “Adipocytokines: mediators linking adipose tissue, inflammation and immunity,” Nature Reviews Immunology, vol. 6, no. 10, pp. 772–783, 2006.

[73] A. Caligiuri, C. Bertolani, C. T. Guerra et al., “Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells,” Hepatology, vol. 47, no. 2, pp. 668–676, 2008.

[74] M. Adachi and D. A. Brenner, “High molecular weight adiponecin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase,” Hepatology, vol. 47, no. 2, pp. 677–685, 2008.

[75] K. Imajo, K. Fujita, M. Yoneda et al., “Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling,” Cell Metabolism, vol. 16, no. 1, pp. 44–54, 2012.

[76] C. Bertolani and F. Marra, “Role of adipocytokines in hepatic fibrosis,” Current Pharmaceutical Design, vol. 16, no. 17, pp. 1929–1940, 2010.

[77] S. S. Choi, W. K. Syn, G. F. Karaca et al., “Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway,” The Journal of Biological Chemistry, vol. 285, no. 47, pp. 36551–36560, 2010.

[78] S. Allefi, I. Petrai, C. Bertolani et al., “Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells,” Hepatology, vol. 42, no. 6, pp. 1339–1348, 2005.
[111] N. Chalasani, Z. Younossi, J. E. Lavine et al., “The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association,” Hepatology, vol. 55, no. 6, pp. 2005–2023, 2012.

[112] J. Weiss, M. Rau, and A. Geier, “Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment,” Deutsches Arzteblatt International, vol. 111, no. 26, pp. 447–452, 2014.

[113] R. R. Mummadi, K. S. Kasturi, S. Chennareddygari, and G. K. Sood, “Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis,” Clinical Gastroenterology and Hepatology, vol. 6, no. 12, pp. 1396–1402, 2008.

[114] J. Dyson and C. Day, “Treatment of non-alcoholic fatty liver disease,” Digestive Diseases, vol. 32, no. 5, pp. 597–604, 2014.

[115] A. Federico, “Fat: a matter of disturbance for the immune system,” World Journal of Gastroenterology, vol. 16, no. 38, p. 4762, 2010.

[116] S. Shono, Y. Habu, M. Nakashima et al., “The immunologic outcome of enhanced function of mouse liver lymphocytes and Kupffer cells by high-fat and high-cholesterol diet,” Shock, vol. 36, no. 5, pp. 484–493, 2011.

[117] T. Geng, A. Sutter, M. D. Harland et al., “SphK1 mediates hepatic inflammation in a mouse model of NASH induced by high saturated fat feeding and initiates proinflammatory signaling in hepatocytes,” Journal of Lipid Research, vol. 56, no. 12, pp. 2359–2371, 2015.

[118] Y. Chen, H. Huang, C. Xu, C. Yu, and Y. Li, “Long non-coding RNA profiling in a non-alcoholic fatty liver disease rodent model: new insight into pathogenesis,” International Journal of Molecular Sciences, vol. 18, no. 1, 2017.